Last Updated: November 9, 2026

Details for Patent: 7,803,788

« Back to Dashboard


Summary for Patent: 7,803,788
Title:Prodrugs of phosphonate nucoleotide analogues
Abstract:A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
Inventor(s):Mark W. Becker, Harlan H. Chapman, Tomas Cihlar, Eugene J. Eisenberg, Gong-Xin He, Michael R. Kernan, William A. Lee, Ernest J. Prisbe, John C. Rohloff, Mark L. Sparacino
Assignee: Gilead Sciences Inc
Application Number:US12/110,829
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,803,788
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,803,788

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,803,788

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1301519 ⤷  Start Trial 2016/014 Ireland ⤷  Start Trial
European Patent Office 1301519 ⤷  Start Trial PA2016009 Lithuania ⤷  Start Trial
European Patent Office 1301519 ⤷  Start Trial 300803 Netherlands ⤷  Start Trial
European Patent Office 1301519 ⤷  Start Trial CA 2016 00012 Denmark ⤷  Start Trial
European Patent Office 1301519 ⤷  Start Trial 16C0013 France ⤷  Start Trial
European Patent Office 1301519 ⤷  Start Trial 122016000024 Germany ⤷  Start Trial
European Patent Office 1301519 ⤷  Start Trial PA2016009,C1301519 Lithuania ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.